# Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients

> **NCT00422084** · PHASE3 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 1272 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Pyronaridine artesunate
- **DRUG:** Coartem® (artemether lumefantrine)

## Key facts

- **NCT ID:** NCT00422084
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-04
- **Final completion:** 2008-05
- **Target enrollment:** 1272 (ACTUAL)
- **Last updated:** 2021-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422084, "Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00422084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*